What's with the AFT Pharmaceuticals (ASX:AFP) share price today?

The AFT Pharmaceuticals (ASX: AFP) share price is still in the starting blocks this morning after the company released a trading update.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AFT Pharmaceuticals Ltd (ASX: AFP) share price is unmoved in early trading this morning after the company released its latest financial results.

AFT Pharmaceuticals shares finished yesterday's trading up 1.65% to $4.30 per share.

The pharmaceutical drug manufacturer's share price has fallen more than 3% over the past 12 months, so let's take a closer look at the company's trading results for the FY21 period to 31 March.

A doctor looks unsure.

Image source: Getty images

AFT Pharmaceuticals report

The Australian pharmaceuticals giant released a positive report overall on the company's FY21 performance, despite noting several challenges it has faced this financial year.

The company's highlight was its revenue, which reached a new record of $113.1 million for the 12-month period up to 31 March, up 7% from the $105.6 million in the prior corresponding period.

AFT Pharmaceuticals' profit after tax was down nearly $4 million, decreasing to $7.8 million down from $12.7 million in the prior year, which the company says "benefited from a one-off gain" of $9.8 million related to the orphan drug
Pascomer.

Its Asian market revenue was also weaker, which the company blamed on the region transitioning towards purchasing higher-margin pharmaceutical products. Meanwhile, the company's gross profit grew by 1% to $48.8 million from $48.3 million and its total assets jumped by nearly 20%, as the company sought to protect inventory amounts.

AFT Pharmaceuticals is now targeting an operating profit range of $18 million to $23 million for FY22.

AFT Pharmaceuticals management comments

AFT Pharmaceuticals chair David Flacks said there was a sense of deserved optimism around the company:

The 2021 financial year has been one of the more challenging in AFT's history as business conditions tightened around the world in the wake of the pandemic.

Nevertheless, as we report another year of record revenue and a more than doubling in underlying earnings, we can look back on the year with a sense of achievement.

AFT Pharmaceuticals share price snapshot

Despite its slight losses this past year, the AFT Pharmaceuticals share price remains very close to its 5-year highs, and more than $1 higher than in January 2020.

AFT Pharmaceuticals shares have rocketed by 16% over the past month since the company signed a major US supply deal, but that's against losses of 15% since 2021 began, as well as its broader 12-month decline.

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Healthcare Shares

Why CSL shares are rebounding today after falling to an 8-year low

CSL shares rebound after hitting an 8-year low as brokers see a potential upside.

Read more »

A doctor looks unsure.
Opinions

3 reasons why the CSL share price could leap 87% to $274!

Here's what to expect from the Biotech stock next.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Healthcare Shares

Beaten down: Are Cochlear, Pro Medicus or CSL shares a better buy right now?

Which struggling healthcare stock could bounce back?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

How high does UBS think CSL shares will go?

This global company is way oversold analysts say.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Macquarie thinks this biotech company's shares could jump more than 50%

Strong royalty flows underpin a bullish valuation.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Growth Shares

3 ASX 200 shares tipped to climb 130% (or more) in the next 12 months

Analysts are bullish about the outlook for these shares.

Read more »

A man sitting at his desktop computer leans forward onto his elbows and yawns while he rubs his eyes as though he is very tired.
Healthcare Shares

Why is this ASX 200 stock sinking 6% today?

This stock is having a tough session. Let's find out what's going on.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

The cutting edge ASX healthcare stock that could rise 50%

Why is the broker bullish on this stock?

Read more »